Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Hydrocortisone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 3/20 | 0.89 |
| ▸ | HIF1A | Q16665 | 12/20 | 0.89 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.89 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.89 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.89 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.89 |
| ▸ | PGR | P06401 | 3/20 | 0.89 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.89 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.89 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.89 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.89 |
| ▸ | SHBG | P04278 | 2/20 | 0.89 |
| ▸ | MAPT | P10636 | 2/20 | 0.89 |
| ▸ | LMNA | P02545 | 3/20 | 0.72 |
| ▸ | AR | P10275 | 1/20 | 0.71 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.71 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.66 |
| ▸ | TSHR | P16473 | 2/20 | 0.66 |
| ▸ | BLM | P54132 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrocortisone SCHEMBL3105442 | 1.00 | HIF1A (0.89) | HIF1AHSD17B10SMN1; SMN2CYP2C19NR3C1 | |
| Hydrocortisone SCHEMBL221483 | 0.99 | HIF1A (0.91) | HIF1AHSD17B10SMN1; SMN2CYP2C19NR3C1 | |
| Hydrocortisone SCHEMBL7665 | 0.99 | HIF1A (0.91) | HIF1AHSD17B10SMN1; SMN2CYP2C19NR3C1 | |
| Hydrocortisone SCHEMBL8801457 | 0.95 | HIF1A (0.98) | HIF1AHSD17B10SMN1; SMN2CYP2C19NR3C1 | |
| Hydrocortisone SCHEMBL1010585 | 0.95 | HIF1A (0.98) | HIF1AHSD17B10SMN1; SMN2CYP2C19NR3C1 | |
| Hydrocortisone SCHEMBL1010584 | 0.95 | HIF1A (0.98) | HIF1AHSD17B10SMN1; SMN2CYP2C19NR3C1 | |
| Hydrocortisone SCHEMBL28908729 | 0.95 | HIF1A (0.86) | HIF1AHSD17B10SMN1; SMN2CYP2C19NR3C1 | |
| Hydrocortisone SCHEMBL4697 | 0.95 | HIF1A (0.86) | HIF1AHSD17B10SMN1; SMN2CYP2C19NR3C1 | |
| Hydrocortisone SCHEMBL3999007 | 0.94 | HIF1A (0.96) | HIF1AHSD17B10SMN1; SMN2CYP2C19NR3C1 | |
| Hydrocortisone SCHEMBL24900238 | 0.94 | HIF1A (1.00) | HIF1AHSD17B10SMN1; SMN2CYP2C19NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4125997-A1 | NEW METHOD TO TREAT THE HEPATOTOXICITY INDUCED BY AMANITINS | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2023-02-08 | — | — | EP | disclosed |
| WO-2021198216-A1 | NEW METHOD TO TREAT THE HEPATOTOXICITY INDUCED BY AMANITINS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2021-10-07 | — | — | WO | disclosed |
| US-20150093434-A1 | LIPOSOMAL COMPOSITIONS OF GLUCOCORTICOID AND GLUCOCORTICOID DERIVATIVES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERSUSALEM (IL) | 2015-04-02 | — | — | US | disclosed |
| US-8932627-B2 | Liposomal compositions of glucocorticoid and glucocorticoid derivatives | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2015-01-13 | — | — | US | disclosed |
| EP-2788041-A1 | ANTIFUNGAL CATHETER | Rochester Medical Corporation (US) | 2014-10-15 | — | — | EP | disclosed |
| CN-104053460-A | ANTIFUNGAL CATHETER | ROCHESTER MEDICAL CORP | 2014-09-17 | — | — | CN | disclosed |
| EP-2738172-A1 | New bicyclic compounds as crac channel modulators | Almirall, S.A. (ES) | 2014-06-04 | — | — | EP | disclosed |
| WO-2013086195-A1 | ANTIFUNGAL CATHETER | ROCHESTER MEDICAL CORPORATION (US) | 2013-06-13 | — | — | WO | disclosed |
| US-20130150828-A1 | ANTIFUNGAL CATHETER | ROCHESTER MEDICAL CORPORATION (US) | 2013-06-13 | — | — | US | disclosed |
| EP-2592078-A1 | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities | Almirall, S.A. (ES) | 2013-05-15 | — | — | EP | disclosed |
| WO-2006027787-A1 | LIPOSOMAL COMPOSITIONS OF GLUCOCORTICOID AND GLUCOCORTICOID DERIVATIVES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2006-03-16 | — | — | WO | disclosed |
| WO-2006027786-A2 | USE OF LIPOSOMAL GLUCOCORTICOIDS FOR TREATING INFLAMMATORY STATES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2006-03-16 | — | — | WO | disclosed |
| CN-1433431-A | Interleukin-1 receptor antagonist-like molecules and uses thereof | AMGEN INC (US) | 2003-07-30 | — | — | CN | disclosed |
| EP-0617631-B1 | SUSTAINED-RELEASE BACTERICIDAL CANNULA | ROCHESTER MEDICAL CORP (US) | 1999-03-17 | — | — | EP | disclosed |
| US-5599321-A | Sustained release bactericidal cannula | ROCHESTER MEDICAL CORPORATION (US) | 1997-02-04 | — | — | US | disclosed |
| US-5482740-A | Sustained release bactericidal cannula | ROCHESTER MEDICAL CORPORATION (US) | 1996-01-09 | — | — | US | disclosed |
| EP-0617631-A4 | SUSTAINED-RELEASE BACTERICIDAL CANNULA. | ROCHESTER MEDICAL CORP (US) | 1995-02-22 | — | — | EP | disclosed |
| EP-0617631-A1 | SUSTAINED-RELEASE BACTERICIDAL CANNULA | ROCHESTER MEDICAL CORPORATION (US) | 1994-10-05 | — | — | EP | disclosed |
| US-5261896-A | Sustained release bactericidal cannula | ROCHESTER MEDICAL CORPORATION (US) | 1993-11-16 | — | — | US | disclosed |
| WO-1993011821-A1 | SUSTAINED-RELEASE BACTERICIDAL CANNULA | ROCHESTER MEDICAL CORPORATION (US) | 1993-06-24 | — | — | WO | disclosed |